FDA Approves Second New Diabetes Drug within Three Days

Bydureon was the first to be approved, now find out what the second new drug is. (See this week's Item #3.)

Nike Fuel Band: Tracks All Physical Activities

Nike has unveiled the Nike+ FuelBand, a product that fits around your wrist and aims to provide a common metric for tracking all physical activities. The FuelBand tracks what the company calls NikeFuel, which lets people compare a game of basketball to a dance class, for example. The band itself tracks activity through oxygen kinetics, which helps it determine whether a user is engaged in an intense sporting activity or sitting at a desk. Nike believes this will provide more precise measurement than simply tracking steps, and allow it to account for the differences across various sports (the device also tracks steps, calories, and time, however).

SPECIAL FEATURE: GLP-1 TEST YOUR KNOWLEDGE, Part 1

Scott is a 57-year-old white male who has been diagnosed with type 2 diabetes mellitus (T2DM) for 4 years. Upon diagnosis, with a glycosylated hemoglobin (A1c) level of 7.3%, he was initiated on lifestyle modifications plus metformin 500 mg twice daily. Eventually his metformin was titrated up to 1000 mg twice daily. After his best attempts at diet, exercise, and adherence to metformin for 1 year, his A1c was down to 6.4%. Scott presents to you most recently, however, with a loss of glycemic control despite continued best efforts on his part. His A1c has climbed to 7.7%, and you decide it is time to initiate another antihyperglycemic agent in addition to his metformin. At this visit his body mass index is 32 kg/m², and his waist circumference is 46 inches.

Question 1: Which of the following represents the best choice as a next step for this patient, especially according to the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) algorithm for treatment of T2DM?...For the complete question and answer just follow this link.